Effects of nicorandil on myocardial infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:study design and protocol for the randomized controlled trial

作     者：Xiao-Si JIANG Li-Chao TIAN Zi-Chao JIANG Yu-Ting ZOU Ping LI Xin-Chun YANG Xi SU Jin-Wen TIAN Bei SHI Zong-Zhuang LI Yong-Jun LI Ren-Qiang YANG Geng QIAN Yun-Dai CHEN Xiao-Si JIANG;Li-Chao TIAN;Zi-Chao JIANG;Yu-Ting ZOU;Ping LI;Xin-Chun YANG;Xi SU;Jin-Wen TIAN;Bei SHI;Zong-Zhuang LI;Yong-Jun LI;Ren-Qiang YANG;Geng QIAN;Yun-Dai CHEN

作者机构：Department of Cardiologythe First Medical Center of Chinese PLA General HospitalBeijingChina The School of MedicineNankai UniversityTianjinChina Department of Cardiologythe First People's Hospital of YunlinGuangxiChina Department of CardiologyBeijing Chaoyang HospitalCapital Medical UniversityBeijingChina Department of CardiologyWuhan Asia Heart HospitalWuhanChina Department of CardiologyHainan Hospital of PLA General HospitalHainanChina Department of CardiologyAffiliated Hospital of Zunyi Medical CollegeGuizhouChina Department of CardiologyGuizhou Provincial People's HospitalGuizhouChina Department of Cardiologythe Second Hospital of Hebei Medical UniversityHebeiChina Department of Cardiologythe Second Affiliated Hospital of Nanchang UniversityJiangxiChina 

出 版 物：《Journal of Geriatric Cardiology》 (老年心脏病学杂志（英文版）)

年 卷 期：2020年第17卷第8期

页      面：519-524页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the National Key Research and Development program of China(2018ZX09201013) Xinxin Merck Cardiovascular Research Fund(2017-CCA-xinxin merck fund-003) 

主　　题：Cardiovascular disease Myocardial infarct size Nicorandil Primary percutaneous coronary intervention ST-segment elevation myocardial infarction 

摘      要：Previous studies have shown that nicorandil has a protective effect on ***,there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction(STEMI)compared to the current standard of percutaneous coronary intervention(PCI)*** CHANGE(China-Administration of Nicorandil Group)study is a multicenter,prospective,randomized,double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China,aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocardial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.